Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study.

Belcastro V, Costa C, Galletti F, Pisani F, Calabresi P, Parnetti L

Clinica Neurologica, Università degli Studi di Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy.

Levetiracetam (LEV) monotherapy was investigated in 25 patients with advanced Alzheimer's disease (AD) and new-onset epileptic seizures in a prospective open-label study. At a daily dose of 1000-1500 mg, 72% were seizure-free for at least one year; 16% discontinued for untolerability; 8% were unresponsive; 4% were lost to follow-up. These results suggest the need for controlled studies to confirm if LEV can be a first-choice drug in AD.

Published 20 September 2007 in Eur J Neurol, 14(10): 1176-8.
Full-text of this article is available online (may require subscription).

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.